novartis (biotechcompany)

literal strings: novartis, NOVARTIS, Novartis

Help NELL Learn!

NELL wants to know if these beliefs are correct.
If they are or ever were, click thumbs-up. Otherwise, click thumbs-down.

• novartis is a biotech company     
• novartis is a company     
• novartis has acquired chiron (biotechcompany)     
• aliskiren is a drug worked on by novartis (biotechcompany)     
• benazepril is a drug worked on by novartis (biotechcompany)     
• exforge_hct is a drug worked on by novartis (biotechcompany)     

categories

• biotechcompany(100.0%)
• SEAL @209 (100.0%) on 14-feb-2011 [ 1 2 3 ] using novartis
• CPL @1109 (64.5%) on 12-jun-2018 [ "company acquired by _" "biotech firms like _" "rival drug from _" "pharmaceutical companies , including _" "inhibitor manufactured by _" "unrestricted grant from _" "consultancy fees from _" "Stock Ratings information for _" "speaker fees from _" "corporate alliance with _" "research grant support from _" "Client companies include _" "MNCs like _" "pharmaceutical companies , like _" "independent subsidiary of _" "cancer drug from _" "Industrial partners include _" "exclusive worldwide license agreement with _" "drug , manufactured by _" "drug companies including _" "exclusive license agreement with _" "IAMC Active member with _" "life science companies such as _" "safety monitoring boards for _" "discovery efforts at _" "medicine manufactured by _" "compounds discovered by _" "multinationals like _" "animal health division of _" "FDA has asked _" "Ritalin , manufactured by _" "medicine made by _" "_ is an equal opportunity employer M/F/D/V" "_ has been an industry pioneer" "corn developed by _" "_ developed the drug" "drug is manufactured by _" "_ is a healthcare company" "dividend stock ratings information for _" "drug manufactured by _" "speakersbureau for _" "global firms like _" "drug made by _" "drug , made by _" "maize developed by _" "first marketed by _" "product development positions at _" "products giant _" "antidepressant made by _" "industrial giants like _" "action lawsuits have been filed against _" "Active member with _" "drug was developed by _" "drug is being developed by _" "drug marketed by _" "collaboration agreement with _" "clinical trial sponsored by _" "honoraria from _" "_ 's global business units" "_ 's GM maize" "players covered are _" "drug discovery at _" "class action lawsuits have been filed against _" "drug giants like _" "collaborative research agreement with _" "_ is developing the drug" "_ received an approvable letter" "_ hopes the drug" "_ informed the FDA" "compound developed by _" "sciences giant _" "_ announced the FDA" "global majors such as _" "vaccine being developed by _" "new vaccine from _" "_ has marketing rights" "medical affairs for _" "drug , produced by _" "unrestricted grants from _" "pharma companies like _" "ratings information for _" "unrestricted educational grant provided by _" "education grant from _" "experimental drug from _" "medical representative for _" "_ immediately cease the dissemination" "educational grant from _" "cancer drug developed by _" "biotechnology companies , such as _" "drugs are manufactured by _" "cancer treatment developed by _" "business unit of _" "major pharmaceutical companies such as _" "drug makers such as _" "molecule developed by _" "pharmaceutical division of _" "biotech giants like _" "biotechnology companies , including _" "biotech companies such as _" "unrestricted educational grant from _" "medication manufactured by _" "engineering companies like _" "big pharmaceutical companies such as _" "_ withdrew the drug" "pharmaceutical giants like _" "medication made by _" "drug business of _" "_ also announced layoffs" "major pharmaceutical companies like _" "Ritalin , made by _" "key leadership role at _" "pharmaceutical firms like _" "pharmaceutical representative for _" "biotech giant _" "_ ' new plant" "drug development at _" "drugs giant _" "educational activities from _" "global business unit of _" "global companies like _" "vaccine produced by _" "FDA has required _" "majority-owned subsidiary of _" "pharmaceutical rep for _" "drugmakers like _" "drug company called _" "brand name owned by _" "biotechnology companies such as _" "international firms , including _" "trial was supported by _" "_ signed a licensing agreement" "_ sells the drug" "_ offers a diversified portfolio" "FDA instructed _" "_ 's Endeavor" "consulting fees from _" "pharmaceutical firms such as _" "seed companies like _" "_ 's second-biggest seller" "several pharmaceutical companies , including _" "trial was funded by _" "vaccines manufactured by _" "vaccine developed by _" "speakers bureaus for _" "_ is seeking FDA approval" "_ has made an equity investment" "you purchase is manufactured by _" "worldwide license agreement with _" "worldwide agreement with _" "wonder drug from _" "vaccine , produced by _" "_ uses data networks" "FDA required _" "drugmakers , such as _" "products recalled by _" "acid was obtained from _" "vaccines division of _" "It is marketed by _" "Ratings information for _" "market players covered are _" "pharma major _" "_ obtained an option" "Job cuts at _" "predecessor companies of _" "vaccine made by _" "pharmaceutical companies including _" "biotech companies like _" "SLN had previously been issued to _" "multinational companies such as _" "major pharmaceutical companies , including _" "drug is marketed by _" "milestone payment from _" "_ has strategic alliance" "major corporations such as _" "_ submitted an NDA" "sales last year for _" "research support from _" "pharmaceutical company named _" "pharmaceutical subsidiary of _" "_ submitted a new drug application" "biotech firms such as _" "industry career at _" "multinational organizations such as _" "product liability lawsuit against _" "major pharmaceutical companies including _" "pharmaceuticals division of _" "study was sponsored by _" "_ manufactures a drug" "drug companies , such as _" "pharmaceuticals giant _" "drug companies like _" "_ donates products" "_ 's Foradil" "lecture fees from _" "inhibitor developed by _" "pharmaceutical companies , such as _" "honorariums from _" "drugs made by _" "drug major _" "atypical antipsychotic medications , including _" "_ is the second-largest supplier" "_ made an equity investment" "independent educational grant from _" "Other positions held at _" "science companies such as _" "milestone payments from _" "medicine is manufactured by _" "consulting fee from _" "co-development agreement with _" "pharmaceutical companies like _" "educational grants from _" "corn made by _" "it is marketed by _" "pharma giant _" "Drug companies like _" "speaker bureau for _" "_ misled doctors" "Pharmaceutical companies like _" "_ faces lawsuits" "such major corporations as _" "private corporations like _" "_ suspend sales" "trial was sponsored by _" "Dividend Stock Ratings information for _" "British subsidiary of _" "large multinational companies such as _" "lecture honoraria from _" "drug being developed by _" "drug companies , including _" "_ is an international pharmaceutical company" "stock ratings information for _" "biotech companies , including _" "_ paid illegal kickbacks" "medication you purchase is manufactured by _" "safety monitoring board for _" "commercialization agreement with _" "drug discovered by _" "warning letter sent to _" "research collaboration agreement with _" "grant support from _" "_ is a pharmaceutical company" "It is manufactured by _" "monitoring boards for _" "flu vaccine made by _" "travel assistance from _" "multinational corporations like _" "prescription drug manufactured by _" "pharmaceutical giants such as _" "drug makers like _" "unrestricted research grants from _" "detailed dividend stock ratings information for _" "pharma companies including _" "Federal Circuit denied _" "healthcare clients including _" "in-licensing agreement with _" "collaboration deal with _" "multinational companies , such as _" "AB-rated generic equivalent of _" "_ owns U.S. Patent No." "vaccine manufactured by _" "worldwide licensing agreement with _" "Pharma companies like _" "FDA asked _" "_ 's blockbuster drug" "_ sought FDA approval" "patent held by _" "It is currently marketed by _" "biologics at _" "pharmaceutical company such as _" "unconditional grant from _" "_ filed a New Drug Application" "pharma companies such as _" "global giants such as _" "grants/research support from _" "biotechnology companies like _" "big pharmaceutical companies like _" "chemical companies such as _" "drug companies , like _" "pharma companies , including _" "educational grant provided by _" "multinationals such as _" "drug sold by _" "vaccine is manufactured by _" "care companies such as _" "pharmaceutical manufactures such as _" "_ collects on-line" "_ 's research chief" "Health division of _" "speaker honoraria from _" "pharmaceutical firms , including _" "acquisition bid by _" "pharmaceutical company called _" "retention obligations imposed on _" "investigator-initiated grant from _" "sciences companies such as _" "vaccine division of _" "discovery collaboration with _" "drug manufacturers like _" "pharmaceutical companies such as _" "View prescription medications of _" "speakers bureau for _" "drug unit of _" "drug developed by _" "drug discovery collaboration with _" "grant/research support from _" "honorarium from _" "_ is a WebMD sponsor" "_ is a multinational pharmaceutical company" "generics business of _" "trial sponsored by _" "multinational corporations such as _" "_ filed an NDA" "clinical research from _" "consultation fees from _" "drug companies such as _" ] using novartis
• company(100.0%)
• MBL @1116 (100.0%) on 12-sep-2018 [ Promotion of ceo:daniel_vasella ceoof biotechcompany:novartis ] using concept:ceo:daniel_vasella
• OE @895 (85.2%) on 10-jan-2015 [ http://www.venturefund.novartis.com/ http://www.venturefund.novartis.com/ http://www.venturefund.novartis.com/ http://www.venturefund.novartis.com/ http://en.wikipedia.org/wiki/Novartis http://en.wikipedia.org/wiki/Novartis http://www.venturefund.novartis.com/ http://www.us.novartis.com/ http://www.bloomberg.com/news/2014-04-22/novartis-to-buy-glaxo-cancer-drugs-sell-animal-health.html http://en.wikipedia.org/wiki/Novartis http://en.wikipedia.org/wiki/Novartis http://en.wikipedia.org/wiki/Novartis http://www.venturefund.novartis.com/ http://en.wikipedia.org/wiki/Novartis http://www.venturefund.novartis.com/ http://www.novartis.com/  ] using novartis
• SEAL @47 (100.0%) on 05-feb-2010 [ 1 ] using novartis

relations

• acquired
• chiron (96.9%)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 already owns DD percent of arg2" "arg1 bought arg2" "arg1 acquired arg2" "arg1 now owns arg2" "arg1 agrees to buy arg2" ] using (novartis, chiron)
• agentcollaborateswithagent
• daniel_vasella (100.0%)
• OE @964 (92.5%) on 13-dec-2015 [ http://online.wsj.com/news/articles/SB10001424052702303775504579394802939589802 http://www.swissinfo.ch/eng/business/Defensive_Vasella_regrets_tarnished_image.html?cid=35237512 http://www.swissinfo.ch/eng/business/Novartis_announces_final_pay-off_deal_for_Vasella.html?cid=36476660 http://www.bbc.co.uk/news/business-21504571 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html  ] using (novartis, daniel_vasella)
• OE @964 (92.5%) on 13-dec-2015 [ http://online.wsj.com/news/articles/SB10001424052702303775504579394802939589802 http://www.swissinfo.ch/eng/business/Defensive_Vasella_regrets_tarnished_image.html?cid=35237512 http://www.swissinfo.ch/eng/business/Novartis_announces_final_pay-off_deal_for_Vasella.html?cid=36476660 http://www.bbc.co.uk/news/business-21504571 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html  ] using (daniel_vasella, novartis)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (novartis, daniel_vasella)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:superpartof" ] using (novartis, daniel_vasella)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (daniel_vasella, novartis)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:superpartof" ] using (daniel_vasella, novartis)
• daniel_vasella (100.0%)
• OE @964 (92.5%) on 13-dec-2015 [ http://online.wsj.com/news/articles/SB10001424052702303775504579394802939589802 http://www.swissinfo.ch/eng/business/Defensive_Vasella_regrets_tarnished_image.html?cid=35237512 http://www.swissinfo.ch/eng/business/Novartis_announces_final_pay-off_deal_for_Vasella.html?cid=36476660 http://www.bbc.co.uk/news/business-21504571 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html  ] using (novartis, daniel_vasella)
• OE @964 (92.5%) on 13-dec-2015 [ http://online.wsj.com/news/articles/SB10001424052702303775504579394802939589802 http://www.swissinfo.ch/eng/business/Defensive_Vasella_regrets_tarnished_image.html?cid=35237512 http://www.swissinfo.ch/eng/business/Novartis_announces_final_pay-off_deal_for_Vasella.html?cid=36476660 http://www.bbc.co.uk/news/business-21504571 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html  ] using (daniel_vasella, novartis)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (novartis, daniel_vasella)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:superpartof" ] using (novartis, daniel_vasella)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (daniel_vasella, novartis)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:superpartof" ] using (daniel_vasella, novartis)
• dr_daniel_vasella (93.8%)
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (dr_daniel_vasella, novartis)
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, dr_daniel_vasella)
• dr_daniel_vasella (93.8%)
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (dr_daniel_vasella, novartis)
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, dr_daniel_vasella)
• agentcontrols
• daniel_vasella (100.0%)
• SEAL @331 (87.5%) on 03-jul-2011 [ 1 2 3 ] using (novartis, daniel_vasella)
• CPL @1094 (98.4%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, daniel_vasella)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:agentcollaborateswithagent" "Y~_X0~concept:agentcollaborateswithagent" "Y~_X0~concept:agentinteractswithagent" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:controlledbyagent" ] using (novartis, daniel_vasella)
• chiron (98.4%)
• CPL @1112 (75.0%) on 20-jul-2018 [ "arg2 Corporation by arg1" "arg2 was subsequently acquired by arg1" ] using (novartis, chiron)
• agentworkedondrug
• aliskiren (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (aliskiren, novartis)
• OE @949 (88.3%) on 20-sep-2015 [ http://www.healio.com/cardiology/highlights-from-acc-scientific-sessions/astronaut-aliskiren-did-not-benefit-hospitalized-hf-patients http://www.pharmatimes.com/article/11-12-23/Novartis_aliskiren_under_European_review_following_safety_concerns.aspx http://cardiobrief.org/2011/12/20/altitude-study-of-aliskiren-terminated-early-by-novartis/  ] using (aliskiren, novartis)
• benazepril (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (benazepril, novartis)
• exforge_hct (100.0%)
• SEAL @263 (100.0%) on 22-may-2011 [ 1 2 3 ] using (exforge_hct, novartis)
• famciclovir (100.0%)
• OE @830 (100.0%) on 13-apr-2014 [   ] using (famciclovir, novartis)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (famciclovir, novartis)
• fluvastatin (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (fluvastatin, novartis)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.statinanswers.com/fluvastatin.htm http://www.ncbi.nlm.nih.gov/pubmed/11336101  ] using (fluvastatin, novartis)
• imatinib (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (imatinib, novartis)
• CPL @1104 (50.0%) on 18-mar-2018 [ "arg1 is marketed by arg2" ] using (imatinib, novartis)
• interceptor (100.0%)
• SEAL @878 (100.0%) on 10-oct-2014 [ 1 ] using (interceptor, novartis)
• nateglinide (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (nateglinide, novartis)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.trialresultscenter.org/DS157-Novartis%20brand%20of%20nateglinide%20clinical%20trials.htm http://en.wikipedia.org/wiki/Nateglinide http://www.drugs.com/mmx/nateglinide.html  ] using (nateglinide, novartis)
• nicotinell (100.0%)
• SEAL @269 (100.0%) on 24-may-2011 [ 1 2 ] using (nicotinell, novartis)
• octreotide (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (octreotide, novartis)
• OE @949 (100.0%) on 20-sep-2015 [ http://www.ncbi.nlm.nih.gov/pubmed/22048969 http://www.bionity.com/en/octreotide.html http://www.healio.com/endocrinology/neuroendocrinology/news/print/endocrine-today/%7Bf90767ef-3047-4988-ae7e-cfa77bebefeb%7D/oral-octreotide-may-offer-new-option-for-patients-with-acromegaly http://www.rsc.org/chemistryworld/2013/02/octreolin-octreotide  ] using (octreotide, novartis)
• sandostatin (100.0%)
• SEAL @221 (100.0%) on 18-mar-2011 [ 1 ] using (sandostatin, novartis)
• tegretol (100.0%)
• SEAL @241 (100.0%) on 22-apr-2011 [ 1 ] using (tegretol, novartis)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.pscard.com/index.cfm/patient-assistance-program/tegretol-to-zyvox/tegretol-xr-patient-assistance/ http://www.drugs.com/answers/anyone-experiencing-trouble-tegretol-200-mg-527672.html https://www.epilepsy.org.uk/news/drugwatch/tegretol-products http://www.pscard.com/index.cfm/patient-assistance-program/tegretol-to-zyvox/tegretol-xr-patient-assistance/ http://www.pscard.com/index.cfm/patient-assistance-program/tegretol-to-zyvox/tegretol-xr-patient-assistance/ http://www.drugs.com/answers/anyone-experiencing-trouble-tegretol-200-mg-527672.html  ] using (tegretol, novartis)
• tegretol_chewable (100.0%)
• OE @877 (100.0%) on 09-oct-2014 [  ] using (tegretol_chewable, novartis)
• SEAL @611 (100.0%) on 09-jul-2012 [ 1 ] using (tegretol_chewable, novartis)
• tegretol_xr (100.0%)
• OE @877 (100.0%) on 09-oct-2014 [ http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152631.htm  ] using (tegretol_xr, novartis)
• SEAL @241 (100.0%) on 22-apr-2011 [ 1 ] using (tegretol_xr, novartis)
• trileptal (100.0%)
• OE @806 (100.0%) on 23-jan-2014 [   ] using (trileptal, novartis)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is a drug manufactured by arg2" ] using (trileptal, novartis)
• SEAL @236 (100.0%) on 16-apr-2011 [ 1 ] using (trileptal, novartis)
• xolair (100.0%)
• OE @1091 (100.0%) on 27-dec-2017 [ https://www.gene.com/media/press-releases/5707/2002-12-18/genentech-and-novartis-submit-amendment- https://www.gene.com/media/press-releases/14551/2013-10-10/fda-files-genentechs-supplemental-biolog https://www.gene.com/media/press-releases/5707/2002-12-18/genentech-and-novartis-submit-amendment-  ] using (xolair, novartis)
• SEAL @269 (87.5%) on 24-may-2011 [ 1 2 3 ] using (xolair, novartis)
• ritalin (99.8%)
• SEAL @241 (99.2%) on 22-apr-2011 [ 1 2 3 4 5 6 7 ] using (ritalin, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 lawsuits were filed against arg2" "arg1 class action lawsuits against arg2" ] using (ritalin, novartis)
• zometa (99.8%)
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg2 under the brand name arg1" "arg2 under the trade names arg1" "arg2 bone drug arg1" ] using (zometa, novartis)
• SEAL @221 (98.4%) on 18-mar-2011 [ 1 2 3 4 5 6 ] using (zometa, novartis)
• femara (99.6%)
• SEAL @221 (99.6%) on 18-mar-2011 [ 1 2 3 4 5 6 7 8 ] using (femara, novartis)
• elidel (99.2%)
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg1 is manufactured and marketed by arg2" "arg1 marketed by arg2" "arg1 is marketed by arg2" ] using (elidel, novartis)
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (elidel, novartis)
• diovan (98.4%)
• SEAL @221 (96.9%) on 18-mar-2011 [ 1 2 3 4 5 ] using (diovan, novartis)
• CPL @1105 (50.0%) on 25-mar-2018 [ "arg2 under the trade name arg1" ] using (diovan, novartis)
• gleevec (98.4%)
• SEAL @236 (93.8%) on 16-apr-2011 [ 1 2 3 4 ] using (gleevec, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 a patent for arg1" "arg2 has secured access to arg1" ] using (gleevec, novartis)
• lucentis (98.4%)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 by Genentech and arg2" "arg1 is marketed by arg2" ] using (lucentis, novartis)
• SEAL @325 (93.8%) on 30-jun-2011 [ 1 2 3 4 ] using (lucentis, novartis)
• zelnorm (98.4%)
• CPL @1105 (87.5%) on 25-mar-2018 [ "arg2 showed that patients taking arg1" "arg2 plans to recall arg1" "arg2 under the trade names arg1" ] using (zelnorm, novartis)
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (zelnorm, novartis)
• comtan (96.9%)
• SEAL @241 (87.5%) on 22-apr-2011 [ 1 2 3 ] using (comtan, novartis)
• CPL @1095 (75.0%) on 17-jan-2018 [ "arg2 for their drug arg1" "arg2 under the trade names arg1" ] using (comtan, novartis)
• exelon (96.9%)
• SEAL @236 (87.5%) on 16-apr-2011 [ 1 2 3 ] using (exelon, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is marketed by arg2" ] using (exelon, novartis)
• famvir (96.9%)
• CPL @1098 (50.0%) on 21-jan-2018 [ "arg1 which is marketed by arg2" ] using (famvir, novartis)
• SEAL @236 (93.8%) on 16-apr-2011 [ 1 2 3 4 ] using (famvir, novartis)
• foradil (96.9%)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" ] using (foradil, novartis)
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (foradil, novartis)
• glivec (96.9%)
• CPL @1103 (75.0%) on 06-mar-2018 [ "arg2 has secured access to arg1" "arg2 a patent for arg1" ] using (glivec, novartis)
• SEAL @269 (87.5%) on 24-may-2011 [ 1 2 3 ] using (glivec, novartis)
• lamisil (96.9%)
• CPL @1104 (50.0%) on 18-mar-2018 [ "arg2 employs some of arg1" ] using (lamisil, novartis)
• SEAL @236 (93.8%) on 16-apr-2011 [ 1 2 3 4 ] using (lamisil, novartis)
• lescol (96.9%)
• SEAL @221 (87.5%) on 18-mar-2011 [ 1 2 3 ] using (lescol, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 under the brand names arg1" "arg2 under the brand name arg1" ] using (lescol, novartis)
• starlix (96.9%)
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (starlix, novartis)
• CPL @1105 (50.0%) on 25-mar-2018 [ "arg2 receives FDA approval for arg1" ] using (starlix, novartis)
• denavir (93.8%)
• SEAL @560 (93.8%) on 03-may-2012 [ 1 2 3 4 ] using (denavir, novartis)
• exforge (93.8%)
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (exforge, novartis)
• CPL @1113 (50.0%) on 03-aug-2018 [ "arg2 hypertension drug arg1" ] using (exforge, novartis)
• tekturna (93.8%)
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (tekturna, novartis)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (tekturna, novartis)
• tofranil (93.8%)
• SEAL @349 (93.8%) on 14-jul-2011 [ 1 2 3 4 ] using (tofranil, novartis)
• companyceo
• daniel_vasella (100.0%)
• CPL @1094 (99.8%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 chief arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• SEAL @212 (99.6%) on 19-feb-2011 [ 1 2 3 4 5 6 7 8 ] using (daniel_vasella, novartis)
• competeswith
• nestle (100.0%)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (nestle, novartis)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, nestle)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (novartis, nestle)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (nestle, novartis)
• nestle (100.0%)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (nestle, novartis)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, nestle)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (novartis, nestle)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (nestle, novartis)
• phillip_morris_international (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (novartis, philip_morris)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (philip_morris, novartis)
• phillip_morris_international (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (novartis, philip_morris)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (philip_morris, novartis)
• telegraph (98.4%)
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (novartis, telegraph)
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (telegraph, novartis)
• telegraph (98.4%)
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (novartis, telegraph)
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (telegraph, novartis)
• controlledbyagent
• daniel_vasella (99.9%)
• SEAL @359 (87.5%) on 23-jul-2011 [ 1 2 3 ] using (daniel_vasella, novartis)
• CPL @1094 (93.8%) on 01-jan-2018 [ "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• OE @1028 (85.1%) on 23-nov-2016 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• mutualproxyfor
• daniel_vasella (100.0%)
• SEAL @566 (75.0%) on 12-may-2012 [ 1 2 ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:mutualproxyfor,concept:agentcontrols" ] using (novartis, daniel_vasella)
• SEAL @566 (75.0%) on 12-may-2012 [ 1 2 ] using (daniel_vasella, novartis)
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg1 chairman arg2" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:mutualproxyfor,concept:agentcontrols" ] using (daniel_vasella, novartis)
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg1 chairman arg2" ] using (novartis, daniel_vasella)
• daniel_vasella (100.0%)
• SEAL @566 (75.0%) on 12-may-2012 [ 1 2 ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:mutualproxyfor,concept:agentcontrols" ] using (novartis, daniel_vasella)
• SEAL @566 (75.0%) on 12-may-2012 [ 1 2 ] using (daniel_vasella, novartis)
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg1 chairman arg2" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:mutualproxyfor,concept:agentcontrols" ] using (daniel_vasella, novartis)
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg1 chairman arg2" ] using (novartis, daniel_vasella)
• organizationhasagent
• daniel_vasella (100.0%)
• CPL @1094 (99.2%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:proxyfor" "Y~_X0~concept:proxyfor,concept:controlledbyagent,concept:proxyfor" "Y~_X0~concept:agentcontrols,concept:mutualproxyfor,concept:proxyfor" "Y~X0~concept:agentcontrols,concept:agentcollaborateswithagent,concept:agentinteractswithagent" "Y~_X0~concept:proxyfor,concept:mutualproxyfor,concept:proxyfor" ] using (daniel_vasella, novartis)
• OE @1009 (90.2%) on 30-jul-2016 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• organizationhasperson
• daniel_vasella (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentleadsorganization" "Y~_X0~concept:agentrepresentsorganization" "Y~_X0~concept:personleadsorganization" "Y~_X0~concept:mutualproxyfor" "Y~_X0~concept:proxyfor" ] using (daniel_vasella, novartis)
• CPL @1094 (99.2%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• organizationhastopmember
• daniel_vasella (99.6%)
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• organizationhiredperson
• daniel_vasella (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:organizationleadbyperson" "Y~_X0~concept:organizationrepresentedbyagent" "Y~_X0~concept:organizationleadbyagent" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:mutualproxyfor" ] using (novartis, daniel_vasella)
• organizationleadbyperson
• daniel_vasella (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:organizationleadbyperson,concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:organizationleadbyagent,concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:proxyof,concept:personbelongstoorganization" ] using (daniel_vasella, novartis)
• SEAL @214 (100.0%) on 22-feb-2011 [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ] using (daniel_vasella, novartis)
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• OE @959 (99.3%) on 04-nov-2015 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• organizationterminatedperson
• daniel_vasella (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:organizationleadbyagent,concept:worksfor,concept:organizationleadbyperson" "Y~_X0~concept:proxyof,concept:agentcontrols,concept:organizationhastopmember" "Y~X0~concept:organizationhastopmember,concept:worksfor,concept:organizationleadbyperson" "Y~_X0~concept:mutualproxyfor,concept:agentcontrols,concept:organizationhastopmember" "Y~X0~concept:proxyof,concept:worksfor,concept:organizationleadbyperson" ] using (novartis, daniel_vasella)
• proxyof
• daniel_vasella (100.0%)
• CPL @1097 (93.8%) on 19-jan-2018 [ "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• OE @1028 (100.0%) on 23-nov-2016 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• SEAL @551 (75.0%) on 10-apr-2012 [ 1 2 ] using (daniel_vasella, novartis)
• superpartoforganization
• chiron (93.8%)
• CPL @1097 (93.8%) on 19-jan-2018 [ "arg1 is being acquired by arg2" "arg1 Corporation by arg2" "arg1 was subsequently acquired by arg2" "arg1 was acquired by arg2" ] using (chiron, novartis)
• worker
• daniel_vasella (100.0%)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:personleadsorganization,concept:worker,concept:agentleadsorganization" "Y~_X0~concept:agentleadsorganization" "Y~_X0~concept:agentrepresentsorganization" "Y~_X0~concept:personleadsorganization" "Y~_X0~concept:agentcontrols" ] using (daniel_vasella, novartis)
• OE @883 (100.0%) on 30-oct-2014 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.novartis.com/newsroom/media-releases/en/2013/1679194.shtml http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)

NELL has only weak evidence for items listed in grey

• acquired
• alcon (biotechcompany)
• CPL @1103 (75.0%) on 06-mar-2018 [ "arg1 is acquiring arg2" "arg1 completed its merger with arg2" ] using (novartis, alcon)
• chiron_corp
• CPL @1114 (50.0%) on 18-aug-2018 [ "arg1 acquired a stake in arg2" ] using (novartis, chiron_corporation)
• neutec_pharma
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 has acquired arg2" "arg1 bought arg2" ] using (novartis, neutec_pharma)
• agentcontrols
• dr_daniel_vasella
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, dr_daniel_vasella)
• joe_jimenez
• CPL @1100 (75.0%) on 31-jan-2018 [ "arg1 chief executive arg2" "arg1 ceo arg2" ] using (novartis, joe_jimenez)
• agentworkedondrug
• accupril
• SEAL @298 (50.0%) on 14-jun-2011 [ 1 ] using (accupril, novartis)
• cubicin
• SEAL @263 (75.0%) on 22-may-2011 [ 1 2 ] using (cubicin, novartis)
• lipitor
• SEAL @298 (50.0%) on 14-jun-2011 [ 1 ] using (lipitor, novartis)
• syntocinon
• SEAL @598 (50.0%) on 19-jun-2012 [ 1 ] using (syntocinon, novartis)
• competeswith
• daily_telegraph
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (novartis, telegraph)
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (telegraph, novartis)
• acquired
• alcon (convention)
• CPL @1103 (75.0%) on 06-mar-2018 [ "arg1 is acquiring arg2" "arg1 completed its merger with arg2" ] using (novartis, alcon)
• germany (country)
• CPL @1107 (50.0%) on 24-may-2018 [ "arg1 last year bought arg2" ] using (novartis, germany)
• germany (sportsteam)
• CPL @1107 (50.0%) on 24-may-2018 [ "arg1 last year bought arg2" ] using (novartis, germany)
• competeswith
• mylan (biotechcompany)
• CPL @1116 (50.0%) on 06-sep-2018 [ "arg1 settles with arg2" ] using (mylan, novartis)
• CPL @1116 (50.0%) on 06-sep-2018 [ "arg1 settles with arg2" ] using (novartis, mylan)
• mylan (drug)
• CPL @1116 (50.0%) on 06-sep-2018 [ "arg1 settles with arg2" ] using (mylan, novartis)
• CPL @1116 (50.0%) on 06-sep-2018 [ "arg1 settles with arg2" ] using (novartis, mylan)
• philip_morris (food)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (novartis, philip_morris)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (philip_morris, novartis)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, philip_morris)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (philip_morris, novartis)
• mylan (magazine)
• CPL @1116 (50.0%) on 06-sep-2018 [ "arg1 settles with arg2" ] using (mylan, novartis)
• CPL @1116 (50.0%) on 06-sep-2018 [ "arg1 settles with arg2" ] using (novartis, mylan)
• philip_morris (university)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (novartis, philip_morris)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (philip_morris, novartis)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, philip_morris)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (philip_morris, novartis)
• philip_morris (writer)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (novartis, philip_morris)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (philip_morris, novartis)